undamentalytics Newsletter
Sign in

Microbot Medical Inc. (MBOT) stock

Add to watchlist

Add holding +

NASDAQ: MBOT Nasdaq Health Care Equipment

Microbot Medical Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds34 adding, 29 cuttingOf 11 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Microbot Medical Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 69% and a beta of 1.8 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results

Earnings per share
-$0.08 against an average estimate of -$0.08: missed by 4.3%
Share reaction
+7.5% in the first session after the results on August 15, 2017, against +0.2% for the S&P 500

Microbot Medical's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.6%
  • 1 week+10.6%
  • 1 month-10.3%
  • This year-48.0%
  • 1 year-53.4%
  • 5 years-85.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 15, 2017

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Announcement
  5. Announcement
  6. Announcement
  7. Leadership
  8. Announcement
  9. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Microbot Medical Inc. valuation models and calculator

No model value for Microbot Medical Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.30 −5% $1m 0%
Next −$0.32 −5% $6m +378%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +8.9% on 90 days ago. In the last 30 days, 1 analyst raised Microbot Medical Inc.'s forecast and 1 cut it.

Consensus EPS forecast Microbot Medical Inc., last 90 days
−$0.40 −$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.28 Current fiscal year, 60 days ago: −$0.31 Current fiscal year, 30 days ago: −$0.30 Current fiscal year, 7 days ago: −$0.30 Current fiscal year, Now: −$0.30 −$0.30 Next fiscal year, 90 days ago: −$0.30 Next fiscal year, 60 days ago: −$0.34 Next fiscal year, 30 days ago: −$0.30 Next fiscal year, 7 days ago: −$0.31 Next fiscal year, Now: −$0.32 −$0.32

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.28−$0.30
60 days ago −$0.31−$0.34
30 days ago −$0.30−$0.30
7 days ago −$0.30−$0.31
Now −$0.30−$0.32

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.08 −$0.08 −4.3%
Mar 2026 −$0.07 −$0.05 +28.6%
Dec 2025 −$0.06 −$0.04 +33.3%
Sept 2025 −$0.06 −$0.07 −16.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

4 analysts, Oct 2026
Buy4100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026134
  2. Sep 202633
  3. Aug 202633
  4. Jul 202633

Counts of recommendations published by analysts covering Microbot Medical Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.9%
of tradable shares
Days to cover
8.33
at average volume
Short interest, 1 month
−15%
to October 15, 2026
Held by institutions
18%
of shares
Held by insiders
0.0%
of shares
Employees
43
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
MBOT+9%−60%−46%−32%+79%−48%
Industry peers (median)−9%−37%−8%−19%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
MBOT58%25%42%50%58%9%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
MBOT−57%−61%−72%−49%−62%−67%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from November 30, 2015 to September 4, 2024. Getting back needed a 107249% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.94 – $2.85
From 52-week high
−63.5%
vs 50-day average
−16.0%
vs 200-day average
−43.5%
Volatility (1 year)
69%
Beta vs S&P 500
1.75

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 2 down
typical move ±7.7%
After a week
0 up, 3 down
typical move ±10.8%
After a month
1 up, 2 down
typical move ±20.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 15, 2017 +7.5% +0.2% −3.8% −0.9%
May 15, 2017 −15.7% +0.5% −28.6% −57.0%
March 23, 2016 0.0% −0.7% 0.0% +3.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$22.1M
Institutions reporting
71
Shares held vs prior quarter
▼ 17.6%
Positions opened / closed
10 / 16

Top buyers and sellers, Q2 2026: 34 institutions bought and 29 sold ; the biggest buyer was Mitsubishi Ufj Asset Management Co., Ltd (+1.3M shares) and the biggest seller CIBC Bancorp Usa Inc (−1.9M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Vanguard Capital Management LLC $5.7M 2.9M 25.6% ▼ 0.1%
Mitsubishi Ufj Asset Management Co., Ltd. $2.5M 1.3M 11.2% New
Blackrock, Inc. $1.8M 902K 8.0% ▲ 5.2%
Geode Capital Management, LLC $1.6M 836K 7.4% ▲ 9.9%
UBS Group AG $1.6M 807K 7.1% ▼ 1.2%
DNB Asset Management As $1.3M 677K 6.0% 0.0%
Stifel Financial Corp $1.2M 590K 5.2% ▲ 2.9%
Marshall Wace, LLP $1.1M 542K 4.8% ▲ 12.7%
Susquehanna International Group, LLP $1M 526K 4.6% ▼ 43.1%
Vanguard Fiduciary Trust Co $840,514 431K 3.8% ▲ 7.7%
State Street Corp $591,960 304K 2.7% 0.0%
Alphacentric Advisors LLC $487,500 250K 2.2% ▲ 25.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Microbot Medical Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 15, 2017 estimated from the company's past filing pattern, not announced

  • August 15, 2017
  • May 15, 2017
  • March 23, 2016
  • November 2, 2015
  • August 6, 2015
  • May 5, 2015

Recent SEC filings

Data status

When each part of this page on Microbot Medical Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Microbot Medical Inc. in brief

What does Microbot Medical Inc. do?
Microbot Medical Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Microbot Medical Inc.'s stock ticker?
Microbot Medical Inc. trades under the ticker MBOT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Microbot Medical Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, Mitsubishi Ufj Asset Management Co., Ltd. and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.